

## REMARKS

Prior to the entry of this amendment, Claims 2-71 were pending and under consideration. With this Amendment, Claim 2-31, 38-40 and 71 have been canceled without prejudice against their reintroduction into this or one or more timely-filed related applications. Thus, after entry of this Amendment, Claims 32-37 and 41-70 are pending and under consideration.

### In the specification

The specification has been amended to update cross-references to related applications. Basis for this amendment is found in the specification at page 1, lines 4-8 and in the patent application transmittal documents filed August 9, 2001.

This amendment does not introduce new matter.

### In the Claims

Claims 2-31, 38-40 and 71 have been cancelled.

This amendment does not introduce new matter.

### Restriction Under 35 U.S.C. § 121


With regard to the Requirement for Restriction under 35 U.S.C. § 121, Applicants elect without traverse Group V, Claims 32-37 and 41-70, drawn to a method of making a transgenic mammal comprising a modified endogenous nucleic acid, wherein the pre-selected target DNA sequence encodes an enzyme.

The species elected is a gene encoding a human enzyme. Claims 32, 37, 42 and 46-64 are believed to be generic to this species.

Applicants submit that Claims 32-37 and 41-70 satisfy all of the statutory requirements for patentability and are in condition for allowance. An early notification of the same is kindly solicited.

Respectfully submitted,  
DORSEY & WHITNEY LLP

Date: December 1, 2003

By:   
John F. Brady  
Reg. No. 39,118

Four Embarcadero Center, Suite 3400  
San Francisco, California 94111-4187  
Telephone: (650) 494-8700  
Facsimile: (650) 494-8771